Anadrol vs Ezetimibe
FDA Approved vs FDA Approved
avoid Mechanism-based · 75% Both Anadrol and Ezetimibe carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Anadrol Ezetimibe
Weight 332.48 Da 409.43 Da
Half-life ~8-9 hours ~22 hours
Type 17-alpha alkylated anabolic steroid (C21H32O3) Azetidinone (C24H21F2NO3)
Key Benefits
Anadrol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Exceptional strength gains, often noticeable within the first week
03 Potent stimulation of erythropoietin and red blood cell production
04 Increased appetite and nutrient partitioning in some users
05 Improved recovery between training sessions
06 Full, round muscle appearance due to intramuscular water and glycogen retention
07 FDA-approved treatment for various forms of anemia
Ezetimibe
01 Reduces LDL cholesterol by 15-20% as monotherapy
02 Complementary mechanism to statins allows additive LDL reduction of 25% when combined
03 Minimal hepatotoxicity, making it suitable alongside hepatotoxic oral AAS
04 Simple once-daily dosing with no titration required
05 No significant impact on CoQ10 levels (unlike statins)
06 Well tolerated with a side effect profile comparable to placebo in clinical trials
07 Proven cardiovascular outcome benefit when added to statin therapy (IMPROVE-IT trial)
08 Helps manage the severe lipid disruption caused by oral steroids like Anavar and Winstrol
Side Effects
Anadrol
Significant water retention and bloating (estrogenic, not aromatase-mediated)
Elevated blood pressure (fluid volume and RBC increase)
Severe liver stress and elevated liver enzymes (AST/ALT)
Back pumps and lower back pain during exercise
Headaches (often blood pressure-related)
Appetite suppression (paradoxical for a mass-building compound)
Lethargy and fatigue (hepatic strain-related)
Acne and oily skin
Suppression of natural testosterone production
Ezetimibe
Gastrointestinal discomfort (diarrhea, abdominal pain) - mild and infrequent, reported at similar rates to placebo
Upper respiratory tract infection (reported in clinical trials but not clearly drug-related)
Fatigue and headache (uncommon, typically transient)
Contraindications
Pre-existing liver disease or significantly elevated liver enzymes
Prostate cancer or breast cancer in males
Nephrotic phase of nephritis
Hypercalcemia (Anadrol can exacerbate calcium levels)
Pregnancy (Category X - causes virilization of the female fetus)
Known hypersensitivity to oxymetholone
Concurrent use of other 17-alpha alkylated oral steroids (compounded liver toxicity)
Known hypersensitivity to ezetimibe or any component of the formulation
Active liver disease or unexplained persistent elevations in hepatic transaminases (when combined with a statin)
Pregnancy and breastfeeding (when used in combination with a statin)
Research Evidence
Anadrol Ezetimibe
Status FDA Approved FDA Approved
References 5 studies 5 studies
Latest 2018 2023
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.